203 related articles for article (PubMed ID: 38402231)
1. Neurophysiological evidence that frontoparietal connectivity and GABA-A receptor changes underpin the antidepressant response to ketamine.
Sumner RL; McMillan RL; Forsyth A; Muthukumaraswamy SD; Shaw AD
Transl Psychiatry; 2024 Feb; 14(1):116. PubMed ID: 38402231
[TBL] [Abstract][Full Text] [Related]
2. Evidence that Subanesthetic Doses of Ketamine Cause Sustained Disruptions of NMDA and AMPA-Mediated Frontoparietal Connectivity in Humans.
Muthukumaraswamy SD; Shaw AD; Jackson LE; Hall J; Moran R; Saxena N
J Neurosci; 2015 Aug; 35(33):11694-706. PubMed ID: 26290246
[TBL] [Abstract][Full Text] [Related]
3. Ketamine: The final frontier or another depressing end?
Sial OK; Parise EM; Parise LF; Gnecco T; Bolaños-Guzmán CA
Behav Brain Res; 2020 Apr; 383():112508. PubMed ID: 32017978
[TBL] [Abstract][Full Text] [Related]
4. Overlap in the neural circuitry and molecular mechanisms underlying ketamine abuse and its use as an antidepressant.
Kokane SS; Armant RJ; Bolaños-Guzmán CA; Perrotti LI
Behav Brain Res; 2020 Apr; 384():112548. PubMed ID: 32061748
[TBL] [Abstract][Full Text] [Related]
5. Bidirectional Homeostatic Regulation of a Depression-Related Brain State by Gamma-Aminobutyric Acidergic Deficits and Ketamine Treatment.
Ren Z; Pribiag H; Jefferson SJ; Shorey M; Fuchs T; Stellwagen D; Luscher B
Biol Psychiatry; 2016 Sep; 80(6):457-468. PubMed ID: 27062563
[TBL] [Abstract][Full Text] [Related]
6. Ketamine and Attentional Bias Toward Emotional Faces: Dynamic Causal Modeling of Magnetoencephalographic Connectivity in Treatment-Resistant Depression.
Gilbert JR; Galiano CS; Nugent AC; Zarate CA
Front Psychiatry; 2021; 12():673159. PubMed ID: 34220581
[TBL] [Abstract][Full Text] [Related]
7. Antidepressant effects of ketamine and the roles of AMPA glutamate receptors and other mechanisms beyond NMDA receptor antagonism.
Aleksandrova LR; Phillips AG; Wang YT
J Psychiatry Neurosci; 2017 Jun; 42(4):222-229. PubMed ID: 28234212
[TBL] [Abstract][Full Text] [Related]
8. A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action.
Naughton M; Clarke G; O'Leary OF; Cryan JF; Dinan TG
J Affect Disord; 2014 Mar; 156():24-35. PubMed ID: 24388038
[TBL] [Abstract][Full Text] [Related]
9. What is the mechanism of Ketamine's rapid-onset antidepressant effect? A concise overview of the surprisingly large number of possibilities.
Strasburger SE; Bhimani PM; Kaabe JH; Krysiak JT; Nanchanatt DL; Nguyen TN; Pough KA; Prince TA; Ramsey NS; Savsani KH; Scandlen L; Cavaretta MJ; Raffa RB
J Clin Pharm Ther; 2017 Apr; 42(2):147-154. PubMed ID: 28111761
[TBL] [Abstract][Full Text] [Related]
10. Two cellular hypotheses explaining the initiation of ketamine's antidepressant actions: Direct inhibition and disinhibition.
Miller OH; Moran JT; Hall BJ
Neuropharmacology; 2016 Jan; 100():17-26. PubMed ID: 26211972
[TBL] [Abstract][Full Text] [Related]
11. Glutamatergic Signaling Drives Ketamine-Mediated Response in Depression: Evidence from Dynamic Causal Modeling.
Gilbert JR; Yarrington JS; Wills KE; Nugent AC; Zarate CA
Int J Neuropsychopharmacol; 2018 Aug; 21(8):740-747. PubMed ID: 29668918
[TBL] [Abstract][Full Text] [Related]
12. The antidepressant effect of ketamine is not associated with changes in occipital amino acid neurotransmitter content as measured by [(1)H]-MRS.
Valentine GW; Mason GF; Gomez R; Fasula M; Watzl J; Pittman B; Krystal JH; Sanacora G
Psychiatry Res; 2011 Feb; 191(2):122-7. PubMed ID: 21232924
[TBL] [Abstract][Full Text] [Related]
13. Relationship of ketamine's antidepressant and psychotomimetic effects in unipolar depression.
Sos P; Klirova M; Novak T; Kohutova B; Horacek J; Palenicek T
Neuro Endocrinol Lett; 2013; 34(4):287-93. PubMed ID: 23803871
[TBL] [Abstract][Full Text] [Related]
14. Storm on predictive brain: A neurocomputational account of ketamine antidepressant effect.
Bottemanne H; Berkovitch L; Gauld C; Balcerac A; Schmidt L; Mouchabac S; Fossati P
Neurosci Biobehav Rev; 2023 Nov; 154():105410. PubMed ID: 37793581
[TBL] [Abstract][Full Text] [Related]
15. TAK-653, an AMPA receptor potentiator with minimal agonistic activity, produces an antidepressant-like effect with a favorable safety profile in rats.
Hara H; Suzuki A; Kunugi A; Tajima Y; Yamada R; Kimura H
Pharmacol Biochem Behav; 2021 Dec; 211():173289. PubMed ID: 34655652
[TBL] [Abstract][Full Text] [Related]
16. Assessment of Relationship of Ketamine Dose With Magnetic Resonance Spectroscopy of Glx and GABA Responses in Adults With Major Depression: A Randomized Clinical Trial.
Milak MS; Rashid R; Dong Z; Kegeles LS; Grunebaum MF; Ogden RT; Lin X; Mulhern ST; Suckow RF; Cooper TB; Keilp JG; Mao X; Shungu DC; Mann JJ
JAMA Netw Open; 2020 Aug; 3(8):e2013211. PubMed ID: 32785636
[TBL] [Abstract][Full Text] [Related]
17. Potential involvement of serotonergic signaling in ketamine's antidepressant actions: A critical review.
du Jardin KG; Müller HK; Elfving B; Dale E; Wegener G; Sanchez C
Prog Neuropsychopharmacol Biol Psychiatry; 2016 Nov; 71():27-38. PubMed ID: 27262695
[TBL] [Abstract][Full Text] [Related]
18. KETAMINE'S MECHANISM OF ACTION: A PATH TO RAPID-ACTING ANTIDEPRESSANTS.
Abdallah CG; Adams TG; Kelmendi B; Esterlis I; Sanacora G; Krystal JH
Depress Anxiety; 2016 Aug; 33(8):689-97. PubMed ID: 27062302
[TBL] [Abstract][Full Text] [Related]
19. Fast-acting antidepressant activity of ketamine: highlights on brain serotonin, glutamate, and GABA neurotransmission in preclinical studies.
Pham TH; Gardier AM
Pharmacol Ther; 2019 Jul; 199():58-90. PubMed ID: 30851296
[TBL] [Abstract][Full Text] [Related]
20. [Ketamine: a neuropsychotropic drug with an innovative mechanism of action].
Guilloux JP; Nguyen TML; Gardier AM
Biol Aujourdhui; 2023; 217(3-4):133-144. PubMed ID: 38018940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
